SCHEMBL878905

SCHEMBL878905

Nc1ncnn2c(CN3CCOCC3)cc(-c3ccc(NC(=O)Nc4ccc(I)cn4)cc3)c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVRL1 P37023 10/20 0.62
MERTK Q12866 2/20 0.54
FLT3 P36888 6/20 0.43
PIK3CD O00329 1/20 0.43
KDR P35968 4/20 0.42
KIT P10721 3/20 0.42
TEK Q02763 1/20 0.42
AXL P30530 1/20 0.40
RET P07949 1/20 0.39
BCR P11274 1/20 0.39
FGFR1 P11362 1/20 0.39
FRK P42685 1/20 0.39
MAPK9 P45984 1/20 0.39
RPS6KA3 P51812 1/20 0.39
PRKCD Q05655 1/20 0.39
DDR1 Q08345 1/20 0.39
MAP4K2 Q12851 1/20 0.39
TNK1 Q13470 1/20 0.39
RPS6KA1 Q15418 1/20 0.39
MAP3K11 Q16584 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL59333 0.91 ACVRL1 (0.62) ACVRL1MERTKFLT3PIK3CDKDR
SCHEMBL58616 0.91 ACVRL1 (0.62) ACVRL1MERTKFLT3PIK3CDKDR
SCHEMBL57288 0.91 ACVRL1 (0.62) ACVRL1MERTKFLT3PIK3CDKDR
SCHEMBL57577 0.88 ACVRL1 (0.59) ACVRL1MERTKFLT3TEKRET
SCHEMBL878975 0.86 ACVRL1 (0.63) ACVRL1MERTKFLT3KDRKIT
SCHEMBL59916 0.85 ACVRL1 (0.66) ACVRL1MERTKFLT3KDRKIT
SCHEMBL59783 0.85 ACVRL1 (0.66) ACVRL1MERTKFLT3KDRKIT
SCHEMBL878979 0.84 ACVRL1 (0.59) ACVRL1MERTKFLT3KDRKIT
SCHEMBL65127 0.83 ACVRL1 (0.65) ACVRL1MERTKFLT3KDRKIT
SCHEMBL58355 0.83 ACVRL1 (0.61) ACVRL1MERTKFLT3KDRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143393-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-27 US disclosed
US-20100063038-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis BAYER HEALTHCARE LLC 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063038-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis CDK4, CDKL4, MKI67 ACVRL1 963/4885MERTK 1905/4885FLT3 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.